NASDAQ:MGRX Mangoceuticals Q4 2025 Earnings Report $0.32 -0.02 (-5.38%) Closing price 05/5/2026 04:00 PM EasternExtended Trading$0.33 +0.01 (+2.56%) As of 05/5/2026 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Mangoceuticals EPS ResultsActual EPS$0.13Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AMangoceuticals Revenue ResultsActual Revenue$0.09 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMangoceuticals Announcement DetailsQuarterQ4 2025Date4/1/2026TimeBefore Market OpensConference Call DateWednesday, April 1, 2026Conference Call Time7:00AM ETConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Mangoceuticals Earnings HeadlinesMangoceuticals (NASDAQ:MGRX) Raised to Sell at Wall Street ZenApril 25, 2026 | americanbankingnews.comMangoceuticals Insider Trading Activity | NASDAQ:MGRX | BenzingaApril 13, 2026 | benzinga.comWhere the SpaceX "Tidal Wave" hits firstThe SpaceX and xAI IPO could trigger one of the largest capital shifts in market history — $1.75 trillion moving at once. When that happens, it doesn't move evenly. Analyst Dylan Jovine has identified a critical hardware supplier tied to the infrastructure Musk is scaling in Memphis. When the S-1 goes public in June, this dependency becomes impossible to ignore. | Behind the Markets (Ad)Mangoceuticals Delays Annual 10-K Yearly FilingMarch 31, 2026 | tipranks.comMangoceuticals, Inc.: Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity ...March 23, 2026 | finanznachrichten.deMangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.March 17, 2026 | globenewswire.comSee More Mangoceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Mangoceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mangoceuticals and other key companies, straight to your email. Email Address About MangoceuticalsMangoceuticals (NASDAQ:MGRX) develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.View Mangoceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Palantir Drops After a Blowout Q1—What Investors Should KnowShopify’s Valuation Crisis Creates Opportunity in 2026onsemi Stock Dips After Earnings: Why the Dip Is BuyableTSLA: 3 Reasons the Stock Could Hit $400 in MayNebius Breaks Out to All-Time Highs—Here's What's Driving It.3 Reasons Analysts Love DexComMonolithic Power Systems: AI Stock Beat, Raised and Upgraded Post-Earnings Upcoming Earnings AppLovin (5/6/2026)ARM (5/6/2026)DoorDash (5/6/2026)Fortinet (5/6/2026)Marriott International (5/6/2026)Warner Bros. Discovery (5/6/2026)Apollo Global Management (5/6/2026)Cencora (5/6/2026)Cenovus Energy (5/6/2026)CVS Health (5/6/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
